Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Class E basic helix-loop-helix protein 23 (BHLHE23) is a member of the bHLH family of transcription factors, which contain a highly conserved basic domain facilitating sequence-specific DNA binding and a helix-loop-helix domain for protein interactions[2][3]. BHLHE23 is thought to function primarily as a transcriptional repressor, modulating gene expression necessary for the differentiation and maintenance of specific pancreatic and neuronal cell types, with particular importance for rod bipolar cell maturation in the retina[2][3]. Its function is crucial for proper neuronal subtype development and retinal circuitry, acting within an evolutionarily conserved transcriptional network that governs neuronal maturation and connectivity in the central nervous system[2][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Class E basic helix-loop-helix protein 23 (BHLHE23).